Genes of SARS-CoV-2 and emerging variants
Sudip Dhakal A and Ian Macreadie A BA School of Science, RMIT University, Bundoora, Vic. 3083, Australia.
B Tel.: +61 402 564 308; Email: ian.macreadie@rmit.edu.au
Microbiology Australia 42(1) 10-12 https://doi.org/10.1071/MA21004
Submitted: 15 February 2021 Accepted: 24 February 2021 Published: 9 April 2021
Journal Compilation © The Authors 2021 Open Access CC BY, published (by CSIRO Publishing) on behalf of the ASM
Abstract
The pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is distinctly different from outbreaks caused by other coronaviruses: SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). The differences in the rapid transmission and severity of human coronaviruses are due to the genetic composition of the virus. SARS-CoV-2 contains genes encoding non-structural proteins (NSPs), structural proteins, and accessory proteins. The NSPs are mainly involved in replication of the virus within the host and inhibition of the host defence system. Structural proteins are involved in viral entry and attachment to host cells, preservation of the core virion and elicit the majority of the immune response. The functions of the accessory proteins are largely unknown. Most focus has been given to structural proteins, especially the spike protein as the strongest vaccine candidate. However, the recent emergence of spike variants and their ability to rapidly transmit and escape neutralisation by vaccine-induced antibodies has threatened the global community. Meanwhile, recent studies of accessory proteins reveal their importance in viral pathogenesis. Hence, proper understanding of the functions of all unknown viral proteins is crucial to devise alternate antiviral strategies.
References
[1] Mackenzie, J.S. and Smith, D.W. (2020) COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiol. Aust. 41, 45–50.| COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t.Crossref | GoogleScholarGoogle Scholar |
[2] V’kovski, P. et al. (2021) Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170.
| Coronavirus biology and replication: implications for SARS-CoV-2.Crossref | GoogleScholarGoogle Scholar | 33116300PubMed |
[3] Howard-Jones, A.R. and Kok, J. (2020) The SARS-CoV-2 ‘perfect storm’: from humble betacoronavirus to global pandemic. Microbiol. Aust. 41, 150–156.
| The SARS-CoV-2 ‘perfect storm’: from humble betacoronavirus to global pandemic.Crossref | GoogleScholarGoogle Scholar |
[4] Yoshimoto, F.K. (2020) The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 39, 198–216.
| The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19.Crossref | GoogleScholarGoogle Scholar | 32447571PubMed |
[5] Zinzula, L. (2021) Lost in deletion: the enigmatic ORF8 protein of SARS-CoV-2. Biochem. Biophys. Res. Commun. 538, 116–124.
| Lost in deletion: the enigmatic ORF8 protein of SARS-CoV-2.Crossref | GoogleScholarGoogle Scholar | 33685621PubMed |
[6] Yang, J. et al. (2020) A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572–577.
| A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.Crossref | GoogleScholarGoogle Scholar | 32726802PubMed |
[7] Thomson, E.C. et al. (2021) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171–1187.e20.
| Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.Crossref | GoogleScholarGoogle Scholar | 33621484PubMed |
[8] Fratev, F. (2020) The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study. bioRxiv , .
| The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: a free energy of perturbation study.Crossref | GoogleScholarGoogle Scholar |
[9] Tegally, H. et al. (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv , .
| Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.Crossref | GoogleScholarGoogle Scholar | 33236025PubMed |
[10] Jangra, S. et al. (2021) The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv , .
| The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.Crossref | GoogleScholarGoogle Scholar | 33532796PubMed |
[11] Burki, T. (2021) Understanding variants of SARS-CoV-2. Lancet 397, 462.
| Understanding variants of SARS-CoV-2.Crossref | GoogleScholarGoogle Scholar | 33549181PubMed |
[12] Fiorentini, S. et al. (2021) First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020. The Lancet Infectious Diseases. , .
| First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020.Crossref | GoogleScholarGoogle Scholar | 33450180PubMed |
[13] Zhang, L. et al. (2020) The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv , .
| The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.Crossref | GoogleScholarGoogle Scholar | 33398265PubMed |
[14] Wang, P. et al. (2021) Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv , .
| Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization.Crossref | GoogleScholarGoogle Scholar | 33688656PubMed |
[15] Singh, K.P. et al. (2020) Therapeutics for COVID-19: established and in development. Microbiol. Aust. 41, 217–223.
| Therapeutics for COVID-19: established and in development.Crossref | GoogleScholarGoogle Scholar |
[16] Flower, T.G. et al. (2021) Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein. Proc. Natl. Acad. Sci. USA 118, e2021785118.
| Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein.Crossref | GoogleScholarGoogle Scholar | 33361333PubMed |
[17] Young, B.E. et al. (2020) Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet 396, 603–611.
| Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study.Crossref | GoogleScholarGoogle Scholar | 32822564PubMed |
[18] Dhakal, S. et al. (2020) Could the severity of COVID-19 be enhanced by ORF10 accessory proteins? Curr. Top. Pept. Protein Res. 21, 97–106.
[19] Ren, Y. et al. (2020) The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell. Mol. Immunol. 17, 881–883.
| The ORF3a protein of SARS-CoV-2 induces apoptosis in cells.Crossref | GoogleScholarGoogle Scholar | 32555321PubMed |
